Combination of targeted therapy (imatinib) with immunotherapy (peginterferon α-2b) to overcome drug resistance and tumor stem cells in gastrointestinal stromal tumors (GIST).

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 10035-10035
Author(s):  
L. L. Chen ◽  
X. Chen ◽  
L. G. Gouw ◽  
R. I. Andtbacka ◽  
K. A. Jones ◽  
...  
Keyword(s):  
Stem Cells ◽  
Drug Resistance ◽  
Targeted Therapy ◽  
Gastrointestinal Stromal Tumors ◽  
Tumor Stem Cells ◽  
Stromal Tumors ◽  
Peginterferon Α

Targeted Therapy in Gastrointestinal Stromal Tumors

2015 ◽  
pp. 163-196 ◽  
Author(s):  
Piotr Rutkowski ◽  
Joanna Przybył ◽  
Agnieszka Wozniak ◽  
Giuseppe Badalamenti
Keyword(s):  
Targeted Therapy ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors

Gastrointestinal Stromal Tumors (GISTs): From Science to Targeted Therapy

2008 ◽  
Vol 23 (2) ◽  
pp. 96-110 ◽  
Author(s):  
R. Sarmiento ◽  
P. Bonginelli ◽  
F. Cacciamani ◽  
F. Salerno ◽  
G. Gasparini
Keyword(s):  
Targeted Therapy ◽  
Tyrosine Kinase ◽  
Gastrointestinal Stromal Tumors ◽  
Kinase Inhibitor ◽  
Mesenchymal Tumors ◽  
Treatment Scenario ◽  
Stromal Tumors ◽  
Imatinib Resistant ◽  
Review Reports ◽  
Molecular Patterns

Gastrointestinal stromal tumors (GISTs) are the most common mesenchymal tumors of the gastrointestinal tract. GISTs represent a distinct category of tumors characterized by oncogenic mutations of the KIT receptor tyrosine kinase in a majority of patients. KIT is useful not only for the diagnosis but also for targeted therapy of this disease. Imatinib, a tyrosine kinase inhibitor, is widely used in advanced and metastatic GISTs. This agent revolutionized the treatment strategy of advanced disease and is being tested in the neoadjuvant and adjuvant settings with encouraging results. New therapeutic agents like sunitinib have now been approved, enriching the treatment scenario for imatinib-resistant GISTs. The present review reports on the peculiar characteristics of this disease through its biology and molecular patterns, focusing on the predictive value of KIT mutations and their correlation with clinical outcome as well as on the activity of and resistance to approved targeted drugs.

A versatile polyion complex can intelligently respond to a tumor microenvironment to eliminate tumor stem cells for enhanced lung cancer targeted therapy

2019 ◽  
Vol 7 (9) ◽  
pp. 3751-3763 ◽  
Author(s):  
Jiulong Zhang ◽  
Xiufeng Zhao ◽  
Chunrong Yang ◽  
Ziyuan Huang ◽  
Menghao Shi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Stem Cells ◽  
Targeted Therapy ◽  
Tumor Microenvironment ◽  
Antitumor Activity ◽  
Tumor Stem Cells ◽  
Polyion Complex ◽  
Cancer Targeted Therapy

A versatile polyion complex was fabricated which could response to tumor microenvironment and possess remarkable tumor penetrating capability with elevated antitumor activity for LCSCs elimination in vivo.

Gastrointestinal stromal tumors (GISTs): from science to targeted therapy

2008 ◽  
Vol 23 (2) ◽  
pp. 96-110 ◽  
Author(s):  
R. Sarmiento ◽  
P. Bonginelli ◽  
F. Cacciamani ◽  
F. Salerno ◽  
G. Gasparini
Keyword(s):  
Targeted Therapy ◽  
Gastrointestinal Stromal Tumors ◽  
Stromal Tumors
Sign in / Sign up

Export Citation Format

Share Document